This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Take a closer look at your untreated PD-L1 negative mNSCLC patients: Meet Bill

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Could KEYTRUDA® (pembrolizumab) in combination with chemotherapy transform treatment expectations for your untreated PD-L1 metastatic non small cell lung cancer patients?*

Take a closer look at how KEYTRUDA in combination with chemotherapy could help your patients in the downloadable patient profile below.

Download Bill’s Profile: 67-year-old male with stage IV non-squamous NSCLC, negative for EGFR and ALK mutations; PD-L1 non-expressor, no liver or brain metastases at diagnosis. Former smoker with a 10 pack-year history.

Find out more information about KEYTRUDA® (pembrolizumab) in metastatic NSCLC:

Click Here


*KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.1
KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.1

References

  1. KEYTRUDA® (pembrolizumab) Summary of Product characteristics (SPC). 25mg/ml concentrate for infusion.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-00943 | Date of Preparation: June 2020